Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines

Journal of Infectious Diseases

Volumn 205, Issue 5, 2012, Pages 818-829

  Barochia, Amisha V ^a   Cui, Xizhong ^a   Sun, Junfeng ^a   Li, Yan ^a   Solomon, Steven B ^a   Migone, Thi Sau ^b   Subramanian, G Mani ^b   Bolmer, Sally D ^b   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; CREATININE; FIBRINOGEN; LACTIC ACID; NORADRENALIN; RAXIBACUMAB; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DOG; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; FLUID RETENTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEMODYNAMIC MONITORING; HEMODYNAMICS; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; SINGLE DRUG DOSE; THERAPY DELAY;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANTHRAX; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BLOOD PRESSURE; DOGS; FLUID THERAPY; HEART RATE; HEMODYNAMICS; NOREPINEPHRINE; SHOCK; STROKE VOLUME; TIME FACTORS;

EID: 84863115426     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir834     Document Type: Article

References (45)

1. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7:933-44. (Pubitemid 33115771)
2. Centers for Disease Control and Prevention (CDC). Update: investigation of bioterrorism-related inhalational anthrax-Connecticut, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:1049-51.
3. Booth MG, Hood J, Brooks TJ, Hart A. Anthrax infection in drug users. Lancet 2010; 375:1345-6.
4. Anthrax outbreak among heroin users in the United Kingdom and Germany. http://www.emcdda.europa.eu/online/annual-report/2010/boxes/p83. Accessed 1 June 2011.
5. Collier RJ, Young JA. Anthrax toxin. Annu Rev Cell Dev Biol 2003; 19:45-70. (Pubitemid 37487342)
6. Sherer K, Li Y, Cui X, Eichacker PQ. Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy. Am J Respir Crit Care Med 2007; 175:211-21. (Pubitemid 46203123)
7. Brossier F, Weber-Levy M, Mock M, Sirard JC. Role of toxin functional domains in anthrax pathogenesis. Infect Immun 2000; 68:1781-6. (Pubitemid 30164799)
8. Pezard C, Berche P, Mock M. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun 1991; 59:3472-7.
9. Stanley JL, Smith H. Purification of factor I and recognition of a third factor of the anthrax toxin. J Gen Microbiol 1961; 26:49-63.
10. Cui X, Li Y, Li X, et al. Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis 2007; 195:572-80. (Pubitemid 46214400)
11. Moayeri M, Crown D, Dorward DW, et al. The heart is an early target of anthrax lethal toxin in mice: a protective role for neuronal nitric oxide synthase (nNOS). PLoS Pathog 2009; 5:e1000456.
12. Warfel JM, Steele AD, D'Agnillo F. Anthrax lethal toxin induces endothelial barrier dysfunction. Am J Pathol 2005; 166:1871-81. (Pubitemid 40734409)
13. Watson LE, Kuo SR, Katki K, et al. Anthrax toxins induce shock in rats by depressed cardiac ventricular function. PLoS One 2007; 2:e466.
14. Watson LE, Mock J, Lal H, et al. Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction. Front Biosci 2007; 12:4670-5.
15. Cui X, Moayeri M, Li Y, et al. Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am J Physiol Regul Integr Comp Physiol 2004; 286:R699-709. (Pubitemid 38375001)
16. Sweeney DA, Cui X, Solomon SB, et al. Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines. J Infect Dis 2010; 202:1885-96.
17. Kirby JE. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect Immun 2004; 72:430-9. (Pubitemid 38018204)
18. Turk BE. Manipulation of host signalling pathways by anthrax toxins. Biochem J 2007; 402:405-17. (Pubitemid 46423878)
19. Xu L, Frucht DM. Bacillus anthracis: a multi-faceted role for anthrax lethal toxin in thwarting host immune defenses. Int J Biochem Cell Biol 2007; 39:20-4. (Pubitemid 44566470)
20. Li Y, Cui X, Su J, et al. Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats. Crit Care Med 2009; 37:1348-54.
21. Sherer K, Li Y, Cui X, et al. Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model. Crit Care Med 2007; 35:1560-7. (Pubitemid 46809321)
22. Walsh JJ, Pesik N, QuinnCP, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007; 44:968-71. (Pubitemid 46452063)
23. Anaraki S, Addiman S, Nixon G, et al. Investigations and controlmeasures following a case of inhalation anthrax in East London in a drum maker and drummer, October 2008. Euro Surveill 2008; 13:pii: 19076.
24. Klempner MS, Talbot EA, Lee SI, Zaki S, Ferraro MJ. Case records of the Massachusetts General Hospital. Case 25-2010. A 24-year-old woman with abdominal pain and shock. N Engl J Med 2010; 363: 766-77.
25. Grabenstein JD. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin Infect Dis 2008; 46:129-36.
26. Health Protection Scotland. Interim clinical guidance for the management of suspected anthrax in drug users. http://www.hps.scot.nhs. uk/anthrax/documents/clinical-guidance-for-use-of-anthrax-immuneglobulin-v12-1- 2010-03-19.pdf. Accessed 1 June 2011.
27. Ramsay CN, Stirling A, Smith J, et al, on behalf of the NHS GGC, on behalf of the Scottish National Outbreak Control Teams. An outbreak of infection with Bacillus anthracis in injecting drug users in Scotland. Euro Surveill 2010; 15:pii: 19465.
28. Cui X, Li Y, Moayeri M, et al. Late treatment with a protective antigendirected monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis 2005; 191:422-34. (Pubitemid 40139768)
29. Minneci PC, Deans KJ, Hansen B, et al. A canine model of septic shock: balancing animal welfare and scientific relevance. Am J Physiol Heart Circ Physiol 2007; 293:H2487-500. (Pubitemid 47610417)
30. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. 2nd ed. New York: Springer, 2003. Statistics for Biology and Health.
31. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. Corrected edition. New York: Springer, 2000. Springer Series in Statistics.
32. Altaweel L, Chen Z, Moayeri M, et al. Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice. Crit Care Med 2011; 39:1439-47.
33. Bolcome RE 3rd, Chan J. Constitutive MEK1 activation rescues anthrax lethal toxin-induced vascular effects in vivo. Infect Immun 2010; 78: 5043-53.
34. Gozes Y, Moayeri M, Wiggins JF, Leppla SH. Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice. Infect Immun 2006; 74:1266-72. (Pubitemid 43185566)
35. Rolando M, Stefani C, Flatau G, et al. Transcriptome dysregulation by anthrax lethal toxin plays a key role in induction of human endothelial cell cytotoxicity. Cell Microbiol 2010; 12:891-905.
36. Kandadi MR, Hua Y, Ma H, et al. Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca21 handling via a NADPH oxidase-dependent mechanism. PLoS One 2010; 5:e13335.
37. Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361:135-44.
38. Subramanian GM, Cronin PW, Poley G, et al. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 2005; 41: 12-20. (Pubitemid 40863738)
39. Hsu LC, Ali SR, McGillivray S, et al. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci USA 2008; 105:7803-8. (Pubitemid 351872719)
40. Popov SG, Villasmil R, Bernardi J, et al. Lethal toxin of Bacillus anthracis causes apoptosis of macrophages. Biochem Biophys Res Commun 2002; 293:349-55. (Pubitemid 34694214)
41. Triantafilou M, Uddin A, Maher S, et al. Anthrax toxin evades Toll-like receptor recognition, whereas its cell wall components trigger activation via TLR2/6 heterodimers. Cell Microbiol 2007; 9:2880-92. (Pubitemid 350066572)
42. Cui X, Su J, Li Y, et al. Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model. Intensive Care Med 2010; 36:148-56.
43. Dal Molin F, Tonello F, Ladant D, et al. Cell entry and cAMP imaging of anthrax edema toxin. EMBO J 2006; 25:5405-13. (Pubitemid 44764149)
44. Kumar P, Ahuja N, Bhatnagar R. Anthrax edema toxin requires influx of calcium for inducing cyclic AMP toxicity in target cells. Infect Immun 2002; 70:4997-5007.
45. Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA 1982; 79:3162-6. (Pubitemid 12008374)